trending Market Intelligence /marketintelligence/en/news-insights/trending/ooq5vyqco1u4cg-vkynfew2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Eisai cancer drug approved as 1st-line treatment in Japan

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Eisai cancer drug approved as 1st-line treatment in Japan

Eisai Co. Ltd. said Treakisym was approved as a first-line treatment in Japan for patients with low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma, or MCL, a cancer of white blood cells.

The drug will be used in combination with rituximab to treat patients. It is already approved as a monotherapy for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma and MCL.

Eisai began marketing Treakisym in late-2010 as part of a licensing agreement with SymBio Pharmaceuticals Ltd.